Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

ImmunityBio, Inc. IBRX

Healthcare  —  Biotechnology
8.44 (0.20) (2.31%) as of 25 Sep
Market cap
$9.2B
P/E
0.0×
Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

ImmunityBio, Inc. (IBRX) Business Profile

Updated before January 2025

Company Overview

ImmunityBio, Inc. (NASDAQ: IBRX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccines to treat and prevent life-threatening diseases, including cancer and infectious diseases. The company was founded in 2014 by Dr. Patrick Soon-Shiong, a renowned physician, surgeon, and entrepreneur known for his groundbreaking work in cancer research and drug development. Headquartered in Culver City, California, ImmunityBio operates with a mission to harness the power of the immune system to create innovative therapies that improve patient outcomes.

Dr. Soon-Shiong serves as the Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. Under his leadership, the company has built a robust pipeline of immunotherapy candidates and established itself as a key player in the biotechnology sector. ImmunityBio’s leadership team also includes experienced executives and scientists with expertise in immunology, oncology, and vaccine development.

Core Business Segments

Immuno-Oncology

ImmunityBio’s primary focus is on immuno-oncology, where it develops therapies designed to activate the immune system to target and destroy cancer cells. Key products and candidates in this segment include:

  • Anktiva (N-803): A novel IL-15 superagonist designed to enhance the activity of natural killer (NK) cells and T cells. Anktiva is being evaluated in combination with other therapies for various cancers, including bladder cancer, non-small cell lung cancer, and pancreatic cancer.
  • T-cell Therapies: ImmunityBio is advancing a pipeline of T-cell-based therapies, including engineered T-cell receptor (TCR) therapies and chimeric antigen receptor (CAR) T-cell therapies, to target solid tumors and hematologic malignancies.

Infectious Diseases

ImmunityBio is also developing vaccines and therapies to combat infectious diseases. Notable programs include:

  • COVID-19 Vaccine: The company has developed a second-generation COVID-19 vaccine candidate that aims to provide broader and longer-lasting immunity by targeting both the spike protein and nucleocapsid protein of the virus.
  • HIV and Tuberculosis: ImmunityBio is working on vaccine candidates and immunotherapies for HIV and tuberculosis, leveraging its expertise in immune system modulation.

Cell Therapy and Regenerative Medicine

ImmunityBio is exploring the potential of cell-based therapies for regenerative medicine applications. This includes the development of NK cell therapies for conditions such as autoimmune diseases and organ transplantation.

Business Model

ImmunityBio operates on a vertically integrated business model that combines research, development, manufacturing, and commercialization. The company generates revenue through partnerships, licensing agreements, and the eventual commercialization of its therapies. Key aspects of its business model include:

  • Research and Development: ImmunityBio invests heavily in R&D to advance its pipeline of immunotherapies and vaccines. The company collaborates with academic institutions, research organizations, and industry partners to accelerate innovation.
  • Manufacturing Capabilities: ImmunityBio has established in-house manufacturing facilities to ensure the production of high-quality biologics and cell therapies. This vertical integration allows the company to maintain control over the supply chain and reduce costs.
  • Strategic Partnerships: The company forms strategic alliances with pharmaceutical companies and healthcare organizations to co-develop and commercialize its products.

Strategic Direction

ImmunityBio is focused on achieving several strategic objectives to drive growth and innovation:

  • Pipeline Expansion: The company aims to expand its pipeline by advancing existing candidates through clinical trials and exploring new therapeutic areas.
  • Global Reach: ImmunityBio is working to establish a global presence by seeking regulatory approvals in key markets and forming international partnerships.
  • Sustainability Goals: The company is committed to sustainable practices in its operations, including reducing its environmental footprint and promoting ethical sourcing of materials.
  • New Product Categories: ImmunityBio is exploring opportunities in areas such as autoimmune diseases, neurodegenerative disorders, and metabolic diseases to diversify its portfolio.

Competitive Landscape

ImmunityBio operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Bristol-Myers Squibb (BMS): A leader in immuno-oncology with a strong portfolio of checkpoint inhibitors and cell therapies.
  • Merck & Co.: Known for its blockbuster immunotherapy Keytruda, Merck is a major competitor in the oncology space.
  • Moderna and BioNTech: These companies are leaders in mRNA vaccine technology and pose competition in the infectious disease segment.
  • Gilead Sciences: A competitor in the HIV and infectious disease space, with a focus on antiviral therapies.

Risk Factors

ImmunityBio faces several risks that could impact its business operations and financial performance:

  • Regulatory Risks: The company’s therapies must undergo rigorous clinical trials and regulatory approvals, which are time-consuming and costly.
  • Market Dependence: ImmunityBio’s success depends on the commercial viability of its pipeline candidates, which may face competition or fail to meet market expectations.
  • Supply Chain Disruptions: The company relies on a complex supply chain for raw materials and manufacturing, which could be disrupted by global events such as pandemics or geopolitical tensions.
  • Financial Risks: As a clinical-stage company, ImmunityBio has yet to achieve profitability and relies on external funding to support its operations.

Recent Developments

  • Bladder Cancer Therapy: ImmunityBio recently announced positive clinical trial results for Anktiva in combination with Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC).
  • COVID-19 Vaccine Progress: The company has advanced its second-generation COVID-19 vaccine candidate into clinical trials, aiming to address emerging variants.
  • Manufacturing Expansion: ImmunityBio has expanded its manufacturing capabilities with the acquisition of a state-of-the-art facility to support the production of cell therapies and biologics.

Investment Considerations

Strengths

  • Innovative Pipeline: ImmunityBio has a diverse pipeline of immunotherapies and vaccines targeting high-value markets.
  • Experienced Leadership: The company benefits from the expertise of Dr. Patrick Soon-Shiong and a seasoned management team.
  • Vertical Integration: In-house manufacturing capabilities provide a competitive advantage in terms of cost and quality control.

Risks

  • Clinical and Regulatory Uncertainty: The success of ImmunityBio’s pipeline depends on the outcomes of clinical trials and regulatory approvals.
  • Financial Dependence: The company’s reliance on external funding poses a risk to its long-term sustainability.
  • Competitive Pressure: ImmunityBio faces intense competition from established players and emerging biotech firms.

Conclusion

ImmunityBio, Inc. is a pioneering biotechnology company with a strong focus on immunotherapy and vaccine development. While the company faces challenges such as regulatory hurdles and financial risks, its innovative pipeline and experienced leadership position it as a promising player in the biotech sector. With a strategic focus on expanding its pipeline, achieving global reach, and exploring new therapeutic areas, ImmunityBio is well-positioned for future growth and success.